1620 Investment Advisors’s Adial Pharmaceuticals ADIL Stock Holding History

1620 Investment Advisors’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-144	Closed	-$2.28K	–	681
2025 Q1	$2.28K	Hold	144	–	–	﹤0.01%	572
2024 Q4	$3.64K	Hold	144	–	–	﹤0.01%	549
2024 Q3	$3.6K	Hold	144	–	–	﹤0.01%	546
2024 Q2	$4.14K	Buy	+144	New	+$5.45K	﹤0.01%	522

Other funds holding ADIL

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

SHIM

Stone House Investment Management Tunkhannock, Pennsylvania $558M AUM 14.72% 1-Year Est. Return

1620 Investment Advisors's ADIL Position: Q2 2025 in Review

1620 Investment Advisors sold out of Adial Pharmaceuticals (ADIL) in Q2 2025, closing a stake of 144 shares — an estimated $2.28K sold.

1620 Investment Advisors first reported a position in ADIL in Q2 2024 and held it in 4 quarters. The position peaked at $4.14K in Q2 2024. 15 funds tracked by Wall St. Rank hold ADIL as of Q2 2025.

1620 Investment Advisors reported no remaining Adial Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
1620 Investment Advisors sold 144 Adial Pharmaceuticals shares in Q2 2025, an estimated $2.28K.
1620 Investment Advisors first reported a position in Adial Pharmaceuticals in Q2 2024 and held it in 4 quarters.
1620 Investment Advisors's Adial Pharmaceuticals position peaked at $4.14K in Q2 2024.
15 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2025.

Based on 1620 Investment Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.